
Medicine and Health
Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles
D. Li, M. Xu, et al.
This study by Dateng Li and colleagues investigates how the combination of casirivimab and imdevimab (CAS + IMD) remarkably speeds up the resolution of COVID-19 symptoms in high-risk outpatients. With significant benefits observed in reducing hospitalization and mortality, particularly for critical symptoms like cough and fever, the research opens new avenues for improving COVID-19 outcomes.
Playback language: English
Related Publications
Explore these studies to deepen your understanding of the subject.